eLife
(Sep 2015)
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Jikui Guan,
Ganesh Umapathy,
Yasuo Yamazaki,
Georg Wolfstetter,
Patricia Mendoza,
Kathrin Pfeifer,
Ateequrrahman Mohammed,
Fredrik Hugosson,
Hongbing Zhang,
Amy W Hsu,
Robert Halenbeck,
Bengt Hallberg,
Ruth H Palmer
Affiliations
Jikui Guan
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Ganesh Umapathy
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Yasuo Yamazaki
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Georg Wolfstetter
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Patricia Mendoza
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Kathrin Pfeifer
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Ateequrrahman Mohammed
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Fredrik Hugosson
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Hongbing Zhang
Five Prime Therapeutics Inc., South San Francisco, United States
Amy W Hsu
Five Prime Therapeutics Inc., South San Francisco, United States
Robert Halenbeck
Five Prime Therapeutics Inc., South San Francisco, United States
Bengt Hallberg
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Ruth H Palmer
ORCiD
Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
DOI
https://doi.org/10.7554/eLife.09811
Journal volume & issue
Vol. 4
Abstract
Read online
Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a range of human cancers, including non-small cell lung cancer and neuroblastoma (Hallberg and Palmer, 2013). Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition to activation of wild-type ALK are able to drive 'superactivation' of activated ALK mutants from neuroblastoma. In conclusion, our data show that ALK is robustly activated by the FAM150A/B ligands and provide an opportunity to develop ALK-targeted therapies in situations where ALK is overexpressed/activated or mutated in the context of the full length receptor.
Keywords
Published in eLife
ISSN
2050-084X (Online)
Publisher
eLife Sciences Publications Ltd
Country of publisher
United Kingdom
LCC subjects
Medicine
Science: Biology (General)
Website
https://elifesciences.org
About the journal
WeChat QR code
Close